| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 17/12/2024 | 12:00 | PR Newswire (US) | Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference | NASDAQ:TBPH | Theravance Biopharma Inc |
| 23/11/2024 | 00:09 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:TBPH | Theravance Biopharma Inc |
| 20/11/2024 | 12:00 | PR Newswire (US) | Theravance Biopharma to Participate in an Upcoming Investor Conference | NASDAQ:TBPH | Theravance Biopharma Inc |
| 14/11/2024 | 15:53 | Edgar (US Regulatory) | Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] | NASDAQ:TBPH | Theravance Biopharma Inc |
| 14/11/2024 | 12:06 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:TBPH | Theravance Biopharma Inc |
| 12/11/2024 | 22:08 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:TBPH | Theravance Biopharma Inc |
| 12/11/2024 | 22:05 | PR Newswire (US) | Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value | NASDAQ:TBPH | Theravance Biopharma Inc |
| 24/10/2024 | 12:00 | PR Newswire (US) | Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024 | NASDAQ:TBPH | Theravance Biopharma Inc |
| 18/10/2024 | 15:00 | PR Newswire (US) | Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease | NASDAQ:TBPH | Theravance Biopharma Inc |
| 05/08/2024 | 22:05 | PR Newswire (US) | Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update | NASDAQ:TBPH | Theravance Biopharma Inc |
| 22/07/2024 | 12:00 | PR Newswire (US) | Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024 | NASDAQ:TBPH | Theravance Biopharma Inc |
| 11/06/2024 | 22:17 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:TBPH | Theravance Biopharma Inc |
| 13/05/2024 | 22:05 | PR Newswire (US) | Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update | NASDAQ:TBPH | Theravance Biopharma Inc |
| 29/04/2024 | 12:00 | PR Newswire (US) | Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024 | NASDAQ:TBPH | Theravance Biopharma Inc |
| 10/04/2024 | 12:00 | PR Newswire (US) | Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024 | NASDAQ:TBPH | Theravance Biopharma Inc |
| 26/02/2024 | 22:05 | PR Newswire (US) | Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | NASDAQ:TBPH | Theravance Biopharma Inc |
| 17/02/2024 | 02:12 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:TBPH | Theravance Biopharma Inc |
| 14/02/2024 | 22:00 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:TBPH | Theravance Biopharma Inc |
| 14/02/2024 | 12:00 | PR Newswire (US) | Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024 | NASDAQ:TBPH | Theravance Biopharma Inc |
| 05/01/2024 | 12:00 | PR Newswire (US) | Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) | NASDAQ:TBPH | Theravance Biopharma Inc |
| 21/12/2023 | 23:10 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:TBPH | Theravance Biopharma Inc |
| 21/12/2023 | 23:00 | PR Newswire (US) | Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors | NASDAQ:TBPH | Theravance Biopharma Inc |
| 18/12/2023 | 12:00 | PR Newswire (US) | Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference | NASDAQ:TBPH | Theravance Biopharma Inc |
| 16/11/2023 | 12:00 | PR Newswire (US) | Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System | NASDAQ:TBPH | Theravance Biopharma Inc |
| 15/11/2023 | 12:00 | PR Newswire (US) | Theravance Biopharma to Participate in the 6th Annual Evercore ISI HealthCONx Conference | NASDAQ:TBPH | Theravance Biopharma Inc |
| 13/11/2023 | 14:00 | PR Newswire (US) | Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) | NASDAQ:TBPH | Theravance Biopharma Inc |
| 07/11/2023 | 22:28 | PR Newswire (US) | Theravance Biopharma, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update | NASDAQ:TBPH | Theravance Biopharma Inc |
| 19/10/2023 | 12:00 | PR Newswire (US) | Theravance Biopharma to Report Third Quarter 2023 Financial Results on November 7, 2023 | NASDAQ:TBPH | Theravance Biopharma Inc |
| 16/10/2023 | 22:13 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:TBPH | Theravance Biopharma Inc |
| 28/08/2023 | 12:05 | PR Newswire (US) | Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders | NASDAQ:TBPH | Theravance Biopharma Inc |